VEC exhibitors

CORPORATE INFORMATION

Although the 22nd EFORT Annual Congress Vienna 2021 has been cancelled, we are pleased to leave here the links and information of our existing corporate partners and sponsors.

EFORT invites you to browse through the Guide of Corporate Partners and Sponsors of the VEChybrid 2021 which represents those EFORT clients that have committed to and confirmed their participation in the 2021 EFORT Annual Congress.

EFORT Industry Database

Back to Exhibitors

3M

3M Corporate Headquarters - 3M Center
MN 55144-1000 St. Paul
United States
Phone: +1-888-364-3577
About Us

At 3M, we apply science in collaborative ways to improve lives daily. Learn more about our company, our people, and the impact we make.

3M touches virtually every part of your life. Our people and technology make the impossible, possible. Every day we apply our science to enhance people’s lives. This is 3M Science. Applied to Life.™

To request more information or a free product trial please click the internet link above or send a meeting request.

Visit www.3m.co.uk/prevena

Area of Business: Medical Solutions
Category: Innovation
Number of Employees worldwide: 10,001+ employees
Founded in: 1902
Products
3M™ Prevena™ Therapy
Prevena Therapy is designed to manage and protect surgical incisions in patients at risk of surgical site complications, including infection. By applying 125mmHg continuous negative pressure for up to 7 days, Prevena Therapy helps to hold incision edges together, reduce oedema and removes fluid and infectious materials away from the incision and into a replaceable canister. Prevena Therapy has been proven to help reduce surgical site complications and improve patient outcomes across multiple surgical specialties. Helping to reduce the burden on healthcare facilities through reduced reoperations and associated additional costs of treatment.
Category: Closed Incision Negative Pressure Therapy
More information
Industry Satellite Symposium
Live Clinical Panel Discussion : Mitigating Surgical Site Complications in High-Risk Patients After Revision Knee Arthroplasty
A recent multi-centre randomised control trial (RCT) published in the Journal of Arthroplasty found that closed incisional Negative Pressure Therapy (ciNPT) significantly reduced the risk of 90-day surgical site complications and readmissions, compared with standard of care in patients undergoing revision total knee arthroplasty. Join the investigators Dr Carlos Higuera and Dr Giles Scuderi on 30 June between 12:30 – 13:30 CEST - for a discussion of the results, the implications of these findings to revision TKA practice, followed by a live panel discussion for audience Q&A chaired by 3M’s Chief Medical Officer, Dr Ron Silverman.
More information
Please contact us by e-Mail to request a meeting.